$0.85
3.00% yesterday
Nasdaq, Aug 12, 09:45 pm CET
ISIN
US43906K1007
Symbol
HOOK

Hookipa Pharma, Inc. Stock price

$0.85
-0.35 29.58% 1M
-1.04 55.29% 6M
-1.16 57.96% YTD
-3.58 80.92% 1Y
-15.95 94.97% 3Y
-106.45 99.21% 5Y
-139.15 99.40% 10Y
-139.15 99.40% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.02 3.00%
ISIN
US43906K1007
Symbol
HOOK
Industry

Key metrics

Basic
Market capitalization
$10.0m
Enterprise Value
$-30.3m
Net debt
positive
Cash
$40.3m
Shares outstanding
12.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.1 | 0.4
EV/Sales
negative | negative
EV/FCF
0.6
P/B
0.3
Financial Health
Equity Ratio
62.0%
Return on Equity
-84.9%
ROCE
-167.9%
ROIC
-554.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.4m | $25.5m
EBITDA
$-72.4m | $-87.0m
EBIT
$-74.9m | $-74.8m
Net Income
$-73.3m | $-32.0m
Free Cash Flow
$-52.9m
Growth (TTM | estimate)
Revenue
-82.5% | -42.0%
EBITDA
-55.3% | -94.3%
EBIT
-50.1% | -67.1%
Net Income
-54.2% | 26.4%
Free Cash Flow
36.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-774.3% | -341.2%
EBIT
-801.0%
Net
-784.0% | -125.5%
Free Cash Flow
-565.4%
More
EPS
$-5.9
FCF per Share
$-4.4
Short interest
0.5%
Employees
85
Rev per Employee
$520.0k
Show more

Is Hookipa Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Hookipa Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Hookipa Pharma, Inc. forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Hookipa Pharma, Inc. forecast:

Hold
57%
Sell
43%

Financial data from Hookipa Pharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
9.35 9.35
83% 83%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
30% 30%
247%
- Research and Development Expense 61 61
29% 29%
655%
-72 -72
55% 55%
-774%
- Depreciation and Amortization 2.50 2.50
24% 24%
27%
EBIT (Operating Income) EBIT -75 -75
50% 50%
-801%
Net Profit -73 -73
54% 54%
-784%

In millions USD.

Don't miss a Thing! We will send you all news about Hookipa Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hookipa Pharma, Inc. Stock News

Neutral
GlobeNewsWire
25 days ago
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, today announced its intention to voluntarily delist from the Nasdaq Capital Market (“Nasdaq”) and to deregister its common stock under Section 12...
Neutral
GlobeNewsWire
6 months ago
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.
Neutral
GlobeNewsWire
6 months ago
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

Company Profile

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its product includes VaxWace and TheraT. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, Katherine Cohen, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

Head office United States
CEO Malte Peters
Employees 85
Founded 2011
Website www.hookipapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today